Author:
Bukhari Shoiab,Henick Brian S.,Winchester Robert J.,Lerrer Shalom,Adam Kieran,Gartshteyn Yevgeniya,Maniar Rohan,Lin Ziyan,Khodadadi-Jamayran Alireza,Tsirigos Aristotelis,Salvatore Mary M.,Lagos Galina G.,Reiner Steven L.,Dallos Matthew C.,Mathew Matthen,Rizvi Naiyer A.,Mor Adam
Subject
General Biochemistry, Genetics and Molecular Biology
Reference34 articles.
1. Safety and tumor responses with lambrolizumab (Anti–PD-1) in melanoma;Hamid;N. Engl. J. Med.,2013
2. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol.,2015
3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010
4. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma;Postow;N. Engl. J. Med.,2015
5. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol.,2015
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献